Cognitive impairment in Alzheimer’s disease could be due to a decline in soluble amyloid-beta

Written by Heather Jones (Future Science Group)


Researchers at the University of Cincinnati (OH, USA) have revealed that the key to treating Alzheimer’s disease might be to restore the levels of amyloid-beta peptide in the brain back to their original state, to prevent the protein from forming amyloid plaques. The study, conducted in collaboration with the Karolinska Institute (Stockholm, Sweden), appears in EClinicalMedicine (published by the Lancet) and follows the US FDA’s recent approval of aducanumab, a new treatment that targets amyloid plaques. It was over 100 years ago that Alois Alzheimer first identified plaques in the brain of patients with the disease. Since then, scientists have...

To view this content, please register now for access

It's completely free